Tisagenlecleucel (Kymriah)

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses tisagenlecleucel (Kymriah) 1.2 × 106 to 6.0 × 108 CAR-positive viable T cells suspended in 1 or more patient-specific infusion bags for single-dose, one-time, IV administration. Indication: For the treatment of adults with relapsed or refractory grade 1, 2, or 3a follicular lymphoma after 2 or more lines of systemic therapy.